Overview

Phase I Study of Marizomib + Panobinostat for Children With DIPG

Status:
Active, not recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This research study is evaluating the safety, tolerability and preliminary efficacy of the drugs marizomib and panobinostat in pediatric patients with diffuse intrinsic pontine glioma (DIPG). The names of the study drugs involved in this study are: - Marizomib - Panobinostat
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Celgene
Secura Bio
Secura Bio, Inc.
Treatments:
Panobinostat